Contrasting Hologic (HOLX) & The Competition
Hologic (NASDAQ: HOLX) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Hologic to related companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.
This table compares Hologic and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
96.4% of Hologic shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 0.8% of Hologic shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Hologic and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Hologic||$2.98 billion||$1.01 billion||13.81|
|Hologic Competitors||$2.02 billion||$430.73 million||-66.96|
Hologic has higher revenue and earnings than its peers. Hologic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current ratings and target prices for Hologic and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hologic currently has a consensus price target of $47.77, suggesting a potential upside of 29.07%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 8.05%. Given Hologic’s stronger consensus rating and higher probable upside, analysts clearly believe Hologic is more favorable than its peers.
Risk & Volatility
Hologic has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Hologic’s peers have a beta of 0.89, indicating that their average share price is 11% less volatile than the S&P 500.
Hologic beats its peers on 11 of the 13 factors compared.
Hologic Company Profile
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.